Faculty, Staff and Student Publications
Publication Date
8-27-2024
Journal
Scientific Reports
Abstract
Osteosarcoma is the most common primary bone malignancy in children and young adults, and it has few treatment options. As a result, there has been little improvement in survival outcomes in the past few decades. The need for models to test novel therapies is especially great in this disease since it is both rare and does not respond to most therapies. To address this, an NCI-funded consortium has characterized and utilized a panel of patient-derived xenograft models of osteosarcoma for drug testing. The exomes, transcriptomes, and copy number landscapes of these models have been presented previously. This study now adds whole genome sequencing and reverse-phase protein array profiling data, which can be correlated with drug testing results. In addition, four additional osteosarcoma models are described for use in the research community.
Keywords
Osteosarcoma, Humans, Animals, Bone Neoplasms, Mice, Xenograft Model Antitumor Assays, Whole Genome Sequencing, Protein Array Analysis, Transcriptome, Disease Models, Animal, Cancer, Bone cancer, Cancer genomics, Cancer models, Sarcoma
DOI
10.1038/s41598-024-69382-8
PMID
39191826
PMCID
PMC11350124
PubMedCentral® Posted Date
August 2024
PubMedCentral® Full Text Version
Post-print
Published Open-Access
yes
Included in
Bioinformatics Commons, Biomedical Informatics Commons, Genetic Processes Commons, Genomics Commons, Musculoskeletal Diseases Commons, Neoplasms Commons, Oncology Commons
